# Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-safety-of-once-weekly-glp-1-receptor-agonist-albiglutide-harmony-2/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Michael A. Nauck,Murray Stewart,Christopher Perkins,Angela R. Jones-Leone,Fred Yang,Caroline Perry,Rickey R. Reinhardt,Marc Rendell |
| Citations | 122 |
| DOI | 10.1007/s00125-015-3795-1 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | hybrid |
| OA URL | https://link.springer.com/content/pdf/10.1007/s00125-015-3795-1.pdf |
| OpenAlex ID | https://openalex.org/W2178377864 |
| PMID | 26577795 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Fred Yang](https://scholariq.org/researchers/fred-yang/)

## Paper journal

- [Diabetologia](https://scholariq.org/journals/diabetologia/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Bariatric Surgery and Outcomes](https://scholariq.org/topics/bariatric-surgery-and-outcomes/)
- [Metabolism, Diabetes, and Cancer](https://scholariq.org/topics/metabolism-diabetes-and-cancer/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.